SynthesisFrontiers in immunology2026
The safety and efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy plus esophagectomy; however, there remains a significant risk of distant metastasis following surgery, which compromises long-term survival among patients. The present study involved a meta-analysis designed to explore the safety and efficacy of neoadjuvant immunochemotherapy (nICT) in patients with locally advanced ESCC. Methods: PubMed, Embase, The Cochrane Library, and Web of Science were searched from inception until June 30, 2025. The extracted data included: pathological complete response (pCR), major pathological response (MPR), objective response rate (ORR), Results: Some 30 studies with a total of 1185 patients were included, wherein the treatment regimen was nICT, without restrictions on the type of immune agents. The results showed that the MPR rate after nICT was 53% (95% confidence interval (CI): 46-59%), and the pooled pCR rate was 32% (95% CI: 29-35%). The pooled Conclusions: This study preliminarily indicates the efficacy and safety of nICT in locally advanced ESCC in China. This combination regimen exhibits superior pCR with tolerable safety profiles, suggesting a new therapeutic strategy for patients with locally advanced ESCC. (CRD42024574607). Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024574607, identifier CRD42024574607.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.